Kenvue Inc. $KVUE Shares Acquired by Parallel Advisors LLC

Parallel Advisors LLC increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 12.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,038 shares of the company’s stock after purchasing an additional 3,801 shares during the quarter. Parallel Advisors LLC’s holdings in Kenvue were worth $712,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Pittenger & Anderson Inc. purchased a new stake in Kenvue during the first quarter worth approximately $30,000. TruNorth Capital Management LLC purchased a new stake in shares of Kenvue in the first quarter valued at approximately $36,000. Truvestments Capital LLC purchased a new stake in Kenvue during the first quarter worth $37,000. Clal Insurance Enterprises Holdings Ltd boosted its position in Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich lifted its position in shares of Kenvue by 120.6% in the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock valued at $41,000 after acquiring an additional 929 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Trading Down 1.4%

Shares of KVUE opened at $18.08 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.15 and a 12-month high of $25.17. The firm has a market capitalization of $34.70 billion, a PE ratio of 24.43, a price-to-earnings-growth ratio of 2.63 and a beta of 0.83. The stock’s fifty day simple moving average is $20.93 and its 200-day simple moving average is $22.09.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same quarter in the prior year, the firm posted $0.32 earnings per share. The firm’s revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is 112.16%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on KVUE shares. Canaccord Genuity Group reduced their target price on Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Evercore ISI lowered their price objective on Kenvue from $25.00 to $23.00 and set an “in-line” rating for the company in a research note on Monday, September 8th. Citigroup decreased their target price on Kenvue from $22.00 to $20.00 and set a “neutral” rating for the company in a research report on Tuesday. Royal Bank Of Canada cut their price objective on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. Finally, Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus price target of $24.04.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.